SI1730191T1 - Imunoglobulin-vezavni hOSM - Google Patents

Imunoglobulin-vezavni hOSM

Info

Publication number
SI1730191T1
SI1730191T1 SI200531371T SI200531371T SI1730191T1 SI 1730191 T1 SI1730191 T1 SI 1730191T1 SI 200531371 T SI200531371 T SI 200531371T SI 200531371 T SI200531371 T SI 200531371T SI 1730191 T1 SI1730191 T1 SI 1730191T1
Authority
SI
Slovenia
Prior art keywords
hosm
immunoglobulin binding
immunoglobulin
binding
binding hosm
Prior art date
Application number
SI200531371T
Other languages
English (en)
Inventor
Jonathan Henry Ellis
Alexandre Eon-Duval
Volker Germaschewski
Christopher Plumpton
Nicholas Timothy Rapson
Michael Robert West
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0407197A external-priority patent/GB0407197D0/en
Priority claimed from GB0407193A external-priority patent/GB0407193D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SI1730191T1 publication Critical patent/SI1730191T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI200531371T 2004-03-30 2005-03-29 Imunoglobulin-vezavni hOSM SI1730191T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0407197A GB0407197D0 (en) 2004-03-30 2004-03-30 Immunoglobulins
GB0407193A GB0407193D0 (en) 2004-03-30 2004-03-30 Immunoglobulins
PCT/GB2005/001147 WO2005095457A2 (en) 2004-03-30 2005-03-29 Immunoglobulins
EP05733043A EP1730191B1 (en) 2004-03-30 2005-03-29 Immunoglobulin binding hosm

Publications (1)

Publication Number Publication Date
SI1730191T1 true SI1730191T1 (sl) 2011-11-30

Family

ID=35064447

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531371T SI1730191T1 (sl) 2004-03-30 2005-03-29 Imunoglobulin-vezavni hOSM

Country Status (25)

Country Link
US (2) US7858753B2 (sl)
EP (2) EP1730191B1 (sl)
JP (1) JP4809828B2 (sl)
KR (1) KR100942849B1 (sl)
AR (1) AR048516A1 (sl)
AT (1) ATE515515T1 (sl)
AU (1) AU2005229457B2 (sl)
BR (1) BRPI0509367A (sl)
CA (1) CA2562953A1 (sl)
CY (1) CY1112192T1 (sl)
DK (1) DK1730191T3 (sl)
HK (1) HK1103747A1 (sl)
HR (1) HRP20110657T1 (sl)
IL (1) IL178119A0 (sl)
MA (1) MA28541B1 (sl)
NO (1) NO20064886L (sl)
NZ (1) NZ550225A (sl)
PE (1) PE20060287A1 (sl)
PL (1) PL1730191T3 (sl)
PT (1) PT1730191E (sl)
RU (5) RU2429245C2 (sl)
SG (1) SG151292A1 (sl)
SI (1) SI1730191T1 (sl)
TW (1) TWI365746B (sl)
WO (1) WO2005095457A2 (sl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR101439828B1 (ko) 2005-11-30 2014-09-17 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
WO2007098547A1 (en) * 2006-03-01 2007-09-07 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
PE20080262A1 (es) 2006-05-25 2008-04-30 Glaxo Group Ltd Anticuerpo humanizado contra interleuquina-18
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
PT2305300E (pt) 2008-07-10 2016-06-16 Toray Industries Composição farmacêutica para o tratamento e prevenção do cancro
CA2733223C (en) 2008-08-05 2018-02-27 Toray Industries, Inc. Pharmaceutical composition comprising anti-caprin-1 antibody for treatment and prevention of cancers
WO2010027797A1 (en) * 2008-08-26 2010-03-11 Macrogenics Inc. T-cell receptor antibodies and methods of use thereof
US8309688B2 (en) * 2008-12-30 2012-11-13 Centocor Ortho Biotech Inc. Monkey homolog of human oncostatin M and methods of use thereof
EP2258723A1 (en) * 2009-06-02 2010-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Treatment of oncostatin M receptor ß mediated heart failure
DK2532680T3 (da) 2010-02-04 2015-07-20 Toray Industries Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
JP5906739B2 (ja) 2010-02-04 2016-04-20 東レ株式会社 癌の治療及び／又は予防用医薬組成物
HUE030102T2 (en) 2010-02-04 2017-04-28 Toray Industries A pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment and / or prevention of cancer
DK2532366T3 (da) 2010-02-04 2017-01-02 Toray Industries Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
JP5742714B2 (ja) 2010-02-04 2015-07-01 東レ株式会社 癌の治療及び／又は予防用医薬組成物
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
RU2600444C2 (ru) * 2010-10-13 2016-10-20 Янссен Байотек, Инк. Человеческие антитела к онкостатину м и способы их применения
SG10201500388PA (en) * 2010-11-23 2015-03-30 Glaxo Group Ltd Antigen binding proteins to oncostatin m (osm)
AU2012290952B2 (en) 2011-08-04 2016-05-05 Toray Industries, Inc. Cancer treatment and/or prevention drug composition
US9175074B2 (en) 2011-08-04 2015-11-03 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
HUE033183T2 (en) 2011-08-04 2017-11-28 Toray Industries A medicament for treating and / or preventing cancer
MX357505B (es) 2012-02-21 2018-07-12 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
WO2013125640A1 (ja) 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び／又は予防用医薬組成物
JP6187255B2 (ja) 2012-02-21 2017-08-30 東レ株式会社 癌の治療及び／又は予防用医薬組成物
DK2818481T3 (da) 2012-02-21 2019-10-14 Toray Industries Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
JP6107654B2 (ja) 2012-03-30 2017-04-05 東レ株式会社 肝臓癌の治療及び／又は予防用医薬組成物
KR102052400B1 (ko) 2012-03-30 2019-12-06 도레이 카부시키가이샤 담낭암의 치료 및/또는 예방용 의약 조성물
ES2692657T3 (es) 2013-05-30 2018-12-04 Kiniksa Pharmaceuticals, Ltd. Proteínas de enlace al antígeno del receptor de oncastatina
TR201819812T4 (tr) 2013-08-09 2019-01-21 Toray Industries Kanserin Tedavisi Ve/Veya Önlenmesi Amacına Yönelik Farmasötik Bileşim
US9550828B2 (en) 2013-09-05 2017-01-24 Boise State University Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
CA2931641C (en) 2013-12-30 2022-05-10 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
KR20220151005A (ko) * 2014-02-24 2022-11-11 다케다 게엠베하 Uti 융합 단백질
US20170327573A1 (en) * 2014-09-24 2017-11-16 Universitá Degli Studi Di Padova Composition to induce bone marrow stem cell mobilization
ES2736948T3 (es) * 2015-01-29 2020-01-09 Ares Trading Sa Inmunoensayos para proteínas altamente cargadas positivamente
US11421028B2 (en) 2016-02-06 2022-08-23 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
CN108883176A (zh) 2016-03-28 2018-11-23 东丽株式会社 癌的治疗和/或预防用药物组合物
GB201614627D0 (en) * 2016-08-30 2016-10-12 Glaxosmithkline Ip Dev Ltd Antigen binding proteins
FR3090637A1 (fr) * 2018-12-21 2020-06-26 Universite De Poitiers Protéine de liaison spécifique capable de se lier spécifiquement à l’oncostatine M humaine (hOSM) et ses utilisations.
US11633457B2 (en) 2019-04-11 2023-04-25 Boise State University Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DK1266965T3 (da) 1991-07-25 2006-09-25 Biogen Idec Inc Rekombinante antistoffer til human terapi
CA2119930C (en) 1991-09-23 2002-10-01 Hendricus R. J. M. Hoogenboom Production of chimeric antibodies - a combinatorial approach
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
RU2139092C1 (ru) 1993-06-03 1999-10-10 Терапьютик Антибодиз Инк. Фрагменты антител в терапии
JP3622208B2 (ja) 1993-06-11 2005-02-23 東ソー株式会社 骨粗鬆症治療方法及び治療薬
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
GB9806530D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
CA2327505A1 (en) 1998-04-28 1999-11-04 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells

Also Published As

Publication number Publication date
AR048516A1 (es) 2006-05-03
IL178119A0 (en) 2006-12-31
HRP20110657T1 (hr) 2011-10-31
EP2404935A1 (en) 2012-01-11
JP2007530068A (ja) 2007-11-01
RU2009108149A (ru) 2010-09-20
NZ550225A (en) 2010-11-26
AU2005229457B2 (en) 2010-11-25
RU2009108148A (ru) 2010-09-20
TWI365746B (en) 2012-06-11
JP4809828B2 (ja) 2011-11-09
TW200602079A (en) 2006-01-16
CA2562953A1 (en) 2005-10-13
PT1730191E (pt) 2011-10-04
KR20060135049A (ko) 2006-12-28
EP1730191A2 (en) 2006-12-13
SG151292A1 (en) 2009-04-30
NO20064886L (no) 2006-12-12
HK1103747A1 (en) 2007-12-28
KR100942849B1 (ko) 2010-02-17
RU2009108147A (ru) 2010-09-20
US7858753B2 (en) 2010-12-28
US20110245470A1 (en) 2011-10-06
DK1730191T3 (da) 2011-10-17
PE20060287A1 (es) 2006-05-16
WO2005095457A3 (en) 2006-04-27
CY1112192T1 (el) 2015-12-09
MA28541B1 (fr) 2007-04-03
ATE515515T1 (de) 2011-07-15
EP1730191B1 (en) 2011-07-06
BRPI0509367A (pt) 2007-09-11
RU2006134477A (ru) 2008-05-10
RU2011121419A (ru) 2012-12-10
RU2429245C2 (ru) 2011-09-20
AU2005229457A1 (en) 2005-10-13
PL1730191T3 (pl) 2011-12-30
US20070286861A1 (en) 2007-12-13
WO2005095457A2 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
HK1103747A1 (en) Immunoglobulin binding hosm
EP1827245A4 (en) BINDING COMPONENT
TWI307630B (en) Immunoglobulins
EP1768999A4 (en) B7-DC BINDING ANTIBODY
ZA201301416B (en) Binding molecules
IL179661A0 (en) Il-13 binding agents
IL181575A0 (en) Anti-ox40l antibodies
IL228033A0 (en) Antibodies
IL182279A0 (en) Angiopoietin-2-specific binding agents
GB0404187D0 (en) Binding agents
EP1710096A4 (en) BINDING DEVICE
GB0420466D0 (en) Anti-glucan antibodies
IL184137A (en) Binding implement for document
ZA200701952B (en) Anti-OX40L antibodies
GB0520523D0 (en) Object binding
IL181492A0 (en) Binding member towards pneumolysin
GB0410627D0 (en) Specific binding members
ZA200610612B (en) Immunoglobulins
ZA200702249B (en) Binding member towards pneumolysin
GB0407197D0 (en) Immunoglobulins
GB0407193D0 (en) Immunoglobulins
GB0423675D0 (en) Immunoglobulins
PL366676A1 (en) Binding spacer
GB0424595D0 (en) Binders
GB0402641D0 (en) Antibodies